Immunotherapy of metastatic renal cell carcinoma. Is clinical use justified with regard to efficacy, side effects and costs?;Immuntherapie des metastasierten Nierenzellkarzinoms. Ist der klinische Einsatz in Anbetracht der Ergebnisse, Nebenwirkungen und Kosten gerechtfertigt?

Urologe - Ausgabe A

Volumn 36, Issue 2, 1997, Pages 130-137

  Oberneder, R ^a   Kriegmair, M ^a   Staehler, M ^a   Hofstetter, A ^a  

^a NONE

Author keywords

cytokines; immunotherapy; prognosis; renal cell carcinoma

Indexed keywords

CYTOKINE;

COST EFFECTIVENESS ANALYSIS; HUMAN; IMMUNOTHERAPY; KIDNEY CANCER; PROGNOSIS; REVIEW;

CARCINOMA, RENAL CELL; COST-BENEFIT ANALYSIS; HUMANS; IMMUNOTHERAPY; KIDNEY NEOPLASMS; NEOPLASM STAGING; PROGNOSIS; SURVIVAL RATE;

EID: 0030892667     PISSN: 03402592     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001200050078     Document Type: Review

References (56)

1. Atzpodien J, Buer J, Probst M, Duensing S, Kirchner H, Ganser A (1996) Clinical and preclinical role of 13-cis-retinoic acid in renal cell carcinoma. Hannover exerience (Meeting abstract). Proc Annu Meet Am Soc Clin Oncol 15: A625
2. Atzpodien J, Kirchner H, de Mulder P et al. (1993) Subcutaneous recombinant interleukin-2 and alpha-interferon in patients with advanced renal cell carcinoma: results of a multicenter Phase II Study. Cancer Biother 8: 289-300
3. Atzpodien J, Kirchner H, Duensing S et al. (1995) Biochemotherapy of advanced metastatic renal-cell carcinoma: results of the combination of interleukin-2, alpha-interferon, 5-fluorouracil, vinblastine, and 13-cis-retinoic acid. World J Urol 13:174-177
4. Atzpodien J, Lopez Hanninen E, Kirchner H et al. (1995) Multiinstitutional home-therapy trial of recombinant human interleukin-2 and interferon alfa-2 in progressive metastatic renal cell carcinoma. J Clin Oncol 13: 497-501
5. Belldegrun A, Figlin R, Danella J, deKernion J (1992) Immunotherapy for Renal Cell Carcinoma. Sem Urol 10: 23-27
6. Belldegrun A, Tso CL, Sakata T et al. (1993) Human renal carcinoma line transfected with interleukin-2 and/or interferon alpha gene(s): implications for live cancer vaccines. J Natl Cancer Inst 85:207-216
7. Bergmann L, Weidmann E, Mitrou PS (1991) Immuntherapie des fortgeschrittenen Nierenzellkarzinoms. Dtsch Med Wochenschr 116: 384-390
8. Bichler KH, Kleinknecht W, Strohmaier WL (1990) Immune Status and Immune Therapy of Renal Cell Carcinoma. Urol Int 45: 269-283
9. Crusinberry R, Williams RD (1991) Immunotherapy for Renal Cell Cancer. Sem Surg Oncol 7: 221-229
10. DeForges A, Rey A, Klink M, Ghosn M, Kramar A, Droz JP (1988) Prognostic factors of adult metastatic renal cell carcinoma: a multivariate analysis. Sem Surg Oncol 4: 149
11. Divgi CR, Bander NH, Scott AM et al. (1994) Phase I radio-immunotherapy trial of I-131 labeled monoclonal antibody G250 in metastatic renal cancer (Meeting abstract). Proc Annu Meet Am Assoc Cancer Res 35: 2999
12. Elson PJ, Witte RS, Trump DL (1988) Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma. Cancer Res 48: 7310
13. Figlin RA, Belldegrun A, Moldawer N, Zeffren J. deKernion J (1992) Concomitant administration of recombinant human interleukin-2 and recombinant interferon alpha-2A: an active outpatient regimen in metastatic renal cell carcinoma. J Clin Oncol 10: 414
14. Figlin RA, Pierce WC, Belldegruin A (1993) Combination Biologic Therapy with Interleukin-2 and Interferon-alfa in the Outpatient Treatment of Metastatic Renal Cell Carcinoma. Sem Oncol 20 [Suppl 9]: 11-15
15. Fossa S, Jones M, Johnson P, Joffc J, Holdener E, Elson P, Ritchie A, Selby P (1995) Interferon-alpha and survival in renal cell cancer. Br J Urol 76: 286-290
16. Fossa SD, Kramar A, Droz JP (1994) Prognostic factors and survival in patients with metastatic renal cell carcinoma treated with chemotherapy or interferon-alpha. Eur J Cancer 30: 1310-1314
17. Golimbu M, Joshi P, Sperber A, Tessler A, Al-Askari S, Morales P (1986) Renal cell carcinoma: survival and prognostic factors. Urology, 27: 291
18. Graham SD (1989) Immunotherapy of renal cell carcinoma. Sem Urol 7: 215-227
19. Gratama JW, Schmitz PIM, Goey H, Lamers CHJ, Stoter G, Bolhuis RLH (1996) Modulation of Immune parameters in patients with metastatic renal-cell cancer receiving combination immunotherapy (IL-2, IFNa and autologous IL-2 activated Lymphocytes). Int J Cancer 65: 152-160
20. Haarstad H, Jacobsen AB, Schjolseth SA, Risberg T, Fossa SD, Schjlseth SA (1994) Interferon-alpha, 5-FU and prednisone in metastatic renal cell carcinoma: a phase II study. Ann Oncol 5: 245-248
21. Haas GP, Hillman GG, Redman BG, Pontes JE (1993) Immunotherapy of renal cell carcinoma. CA Cancer J Clin 43: 177-187
22. Heicappell R, Ackermann R (1990) Rationale for immunotherapy of renal cell carcinoma. Urol Res 18: 357-372
23. Heicappell R, Ackermann R (1991) Current strategies for immunotherapy of renal cell carcinoma. World J Urol 9: 204-209
24. Hieber U, Heim ME (1994) Tumor necrosis factor for the treatment of malignancies. Oncology 51: 142-153
25. Huland F., Heinzer H, Huland H (1994) Inhaled interleukin-2 in combination with low-dose systemic interleukin-2 and interferon alpha in patients with pulmonary metastatic renal-cell carcinoma: effectiveness and toxicity of mainly local treatment. J Cancer Res Clin Oncol 120: 221-228
26. Jones M, Philip T, Palmer P et al. (1993) The Impact of Interleukin-2 on Survival in Renal Cancer: A Multivariate Analysis. Cancer Biother 8: 275-288
27. Kirchner HH, Anton P, Atzpodien J (1995) Adjuvant treatment of locally advanced renal cancer with autologous virus-modified tumor vaccines. World J Urol 13:171-173
28. Kriegmair M, Oberneder R, Hofstetter A (1995) Interferon Alfa and Vinblastine versus Mcdroxyprogesteronacetat in the treatment of metastatic renal cell carcinoma. Urology
29. Kriegmair M, Oberneder R (1995) Die Tumorzellvakzinierung zur Behandlung des Nierenzellkarzinoms. Urologe A 34: 204-207
30. Lissoni P, Barni S, Ardizolla A et al. (1994) Prognostic factors of the clinical response to subcutaneous immunotherapy with Interleukin-2 alone in patients with metastatic renal cell carcinoma. Oncology 51: 59-62
31. Lopez Hänninen E, Kirchner H, Atzpodien J (1996) Interleukin-2 based home therapy of metastatic renal cell carcinoma: risks and benefits in 215 consecutive single institution patients. J Urol 155: 19-25
32. Luiten RM, Coney LR, Fleuren GJ, Warnaar SO, Litvinov SV (1996) Generation of chimeric bispecific G250/anti-CD3 monoclonal antibody, a tool to combat renal cell carcinoma. Br J Cancer 74: 735-744
33. Maldazys JD, deKernion J (1986) Prognostic factors in metastatic renal carcinoma. J Urol 136: 376
34. Marincola FM, White DE, Wise AP, Rosenberg SA (1995) Combination therapy with Interferon Alfa-2a and Interleukin-2 for the treatment of metastatic cancer. J Clin Oncol 13: 1110-1122
35. Merrouche Y, Negrier S, Tolstoshev P et al. (1993) Treatment of patients with advanced cancer using tumor-infiltrating lymphocytes (TIL) transduced with the gene of resistance to neomycin (Meeting abstract). Proc Annu Meet Am Soc Clin Oncol 12: 943
36. Mikisch GH (1995) Gene therapy on renal-cell carcinoma: magic bullet or tragic insanity? World J Urol 13: 178-185
37. Mikisch GH (1995) Molekulare Therapiesteuerung und gentherapeutische Ansätze. Urologe A 34: 189-194
38. Morant R (1994) Treatment of Patients with metastatic renal cell carcinoma with subcutaneous recombinant Interferon-α 2b and continous infusion of recombinant Interleukin-2: A phase II study. Onkologie 17: 254-260
39. Oberneder R, Kriegmair M, Klammert R, Oberbauer B, Hofstetter A (1994) Klinischer Stand der adoptiv-zellulären Immuntherapie. In: Muschter R (Hrsg) Immuntherapic und High Tech in der Urologie. Zuckschwerdt, München, S 10-14
40. Otto T, Goepel M, Lubold HJ, Rübben H (1995) Zytokintherapie des metastasierten Nierenzellkarzinoms. Urologe A 34: 200-203
41. Palmer PA, Vinke J, Philipp T, Negrier S, Atzpodien J (1992) Prognostic factors for survival in patients with advanced renal cell carcinoma treated with recombinant interleukin-2. Ann Oncol 3: 475
42. Palmer PA, Atzpodien J, Philip T et al. (1993) A comparison of 2 modes of administration of recombinant interleukin-2: continuous intravenous infusion alone versus subcutaneous administration plus interferon alpha in patients with advanced renal cell carcinoma. Cancer Biother Winter 8: 289-300
43. Pomer S, Thiele R, Staehler G, Drehmer I, Löhrke H, Schirrmacher V (1995) Tumorvakzination bei Nierenzellkarzinom mit und ohne Interleukin-2 (IL-2) als Adjuvans. Urologe A 34: 215-220
44. Rosenberg SA, Packard BS, Aebersold PM (1988) Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. N Engl J Med 319: 1676-1680
45. Rosenberg SA, Yang JC, Topahan SL et al. (1994) Treatment of 283 consecutive patients with metastastic melanoma or renal cell cancer using high-dose bolus interleukin-2. JAMA 271: 291
46. Schendel DJ, Gansbacher B (1993) Tumor-specific lysis of human renal cell carcinomas by tumor-infiltrating lymphocytes: modulation of recognition through retroviral transduction of tumor cells with interleukin 2 complementary DNA and exogenous alpha interferon treatment. Cancer Res 53: 4020-4025
47. Schendel DJ, Gansbacher B, Oberneder R, Kriegmair M, Hofstetter A, Riethmüller G, Segurado OG (1993) Tumorspecific lysis of human renal cell carcinomas by tumor-infiltrating lymphocytes. I. HLA-AZ-restrict recognition of autolous and allogeneic tumor lines. J immunol 151: 4209-4220
48. Schmitz-Dräger BJ, Jankevicus F, Otto T (1995) Prognostische Faktoren zur Vorhersage des Erfolgs einer Immuntherapie beim metastasierten Nierenzellkarzinom. Urologe A 34: 195-199
49. Schomburg A, Kirchner H, Atzpodien J (1993) Hematotoxicity of Interleukin-2 in man: Clinical effects and comparison of various treatment regimes. Acta Haematol 89: 119-131
50. Schomburg A, Kirchner H, Atzpodien J (1993) Renal, metabolic, and hemodynamic side-effects of interleukin-2 and/ or interferon α: evidence of a risk/benefit advantage of subcutaneous therapy. J Cancer Res Clin Oncol 119: 745-755
51. Sherry RM, Pass HI, Rosenberg SA, Yang JC (1992) Surgical Resection of Metastatic Renal Cell Carcinoma and Melanoma After Response to Interleukin-2-Based Immunotherapy. Cancer 69: 1850-1855
52. Taneja SS, Pierce WC, Figlin RA, Belldegruin A (1994) Immunotherapy for Renal Cell Carcinoma: the Era of Interleukin-2-based Treatment. Urology 45: 911-924
53. Uemura H, Okajima E, Debruyne FM, Oosterwijk E (1994) Immunization with anti-idiotype monoclonal antibodies bearing the internal image of the renal-cell carcinoma-associated antigen G250 induces specific cellular immune responses. Int J Cancer 59: 802-807
54. Walpole ET, Dutcher JP, Sparano J et al. (1993) Survival after phase II treatment of advanced renal cell carcinoma with Taxol or high-dose Interleukin-2. Immunology 13:275-281
55. Wirth M (1991) The current use of Interferons, Interleukin-2 an tumor necrosis factor in renal cell cancer. Urol Int 47: 219-230
56. Wirth M (1993) Immunotherapy for metastatic renal cell carcinoma. Urol Clin North Am 20: 283-295